Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations By Ogkologos - January 27, 2025 114 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Lung05 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Researchers Have Harnessed a Compound from a Common Plant Called Feverfew... August 2, 2019 Accepting Help During Cancer Is Hard, But It Can Benefit You... January 19, 2023 Cancer Research UK releases 2022 gender and ethnicity pay gap reports March 23, 2023 Man Met A Stranger At A Bar Who Was In Need... December 26, 2021 Load more HOT NEWS ESMO Calls for Cancer to Be at the Core of the... FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated... The (un)usual suspects – how early detection research embraces interdisciplinary science The Galleri multi-cancer blood test: what you need to know
